Clinical Trials Logo

Hemophilia A With Inhibitor clinical trials

View clinical trials related to Hemophilia A With Inhibitor.

Filter by:

NCT ID: NCT03619863 Active, not recruiting - Clinical trials for Hemophilia A With Inhibitor

ATHN 7: Hemophilia Natural History Study

ATHN 7
Start date: October 24, 2018
Phase:
Study type: Observational [Patient Registry]

This is a real-world study of the safety of the treatments used for people with hemophilia. The study will follow people with hemophilia A or B from across the country for about 4 years as they receive treatment. The hemophilia treatment center (HTC) physician and participant will decide on the FDA-approved treatment to be used which may include non-factor products, bypassing agents, or clotting factor replacement products. The goal of this research is to study the use of hemophilia treatment products and their outcomes.

NCT ID: NCT03598725 Recruiting - Clinical trials for Hemophilia A With Inhibitor

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

HA-LD-ITI
Start date: January 1, 2016
Phase: Phase 4
Study type: Interventional

The study start on January 18, 2017. The Severe(FⅧ<1%) and moderate hemophilia A (FⅧ1%~5%)children with high titer inhibitor(historical peak inhibitor titer≥5BU ) combining with poor ITI risk(s) were enrolled. The low-dose ITI was alone or combined with immunosuppression.

NCT ID: NCT03407651 Completed - Clinical trials for Hemophilia A With Inhibitor

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Start date: December 18, 2017
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, open-label study designed to evaluate the PK, bioavailability, PD, efficacy and safety of a daily subcutaneous [SC] treatment regimen with MarzAA for bleeding prophylaxis in 12 adult subjects with hemophilia A or B with an inhibitor and history of frequent spontaneous bleeding episodes.

NCT ID: NCT03372993 Completed - Clinical trials for Hemophilia A With Inhibitor

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Start date: June 13, 2016
Phase:
Study type: Observational

This study evaluates the immunogenicity of the biosimilar rFVIIa (AryoSeven) in subjects receiving AryoSeven in real-life clinical practice.

NCT ID: NCT03204539 Terminated - Hemophilia A Clinical Trials

INdividualized ITI Based on Fviii(ATE) Protection by VWF

INITIATE
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The primary goal of the INITIATE trial is to compare the clinical outcome of individualized lot selection to random lot selection utilizing one plasma-derived von Willebrand factor (VWF)/coagulation factor (FVIII) complex concentrate for immune tolerance induction (ITI) in subjects with congenital Hemophilia A, FVIII activity ≤2%, and a historical high-titer inhibitor [≥5 Bethesda Unit (BU)].

NCT ID: NCT02554526 Not yet recruiting - Clinical trials for Hemophilia A With Inhibitor

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Start date: September 2015
Phase: N/A
Study type: Observational

Using whole blood samples and plasma samples obtained from some hemophilia A patients with inhibitors, the investigators will perform the coagulation assessment in the co-presence of aPCC and factor VIII by comprehensive coagulation assays and flow chamber analysis under blood flow conditions.

NCT ID: NCT00166387 Completed - Clinical trials for Hemophilia A With Inhibitor

Hemophilia Inhibitor Genetics Study (HIGS)

Start date: April 2003
Phase: N/A
Study type: Observational

Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored. The aim of the HIGS is to identify these genetic factors.